{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:36:54Z","timestamp":1777394214461,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10147-023-02359-1","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T10:02:31Z","timestamp":1685008951000},"page":"1092-1100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation"],"prefix":"10.1007","volume":"28","author":[{"given":"Soshi","family":"Kadena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-8183","authenticated-orcid":false,"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"7","key":"2359_CR1","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1200\/JCO.2009.26.0133","volume":"28","author":"MR Cooperberg","year":"2010","unstructured":"Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28(7):1117\u20131123","journal-title":"J Clin Oncol"},{"issue":"4","key":"2359_CR2","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618\u2013629","journal-title":"Eur Urol"},{"issue":"9","key":"2359_CR3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/jama.2018.0587","volume":"319","author":"AU Kishan","year":"2018","unstructured":"Kishan AU, Cook RR, Ciezki JP et al (2018) Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9\u201310 prostate cancer. JAMA 319(9):896\u2013905","journal-title":"JAMA"},{"key":"2359_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02314-0","author":"Y Imai","year":"2023","unstructured":"Imai Y, Urabe F, Iwatani K et al (2023) Comparison of outcomes in high-risk prostate cancer patients treated with low-\/high-dose-rate brachytherapy plus external beam radiotherapy. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-023-02314-0","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"2359_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/jrr\/rrt128","volume":"55","author":"H Ishiyama","year":"2014","unstructured":"Ishiyama H, Satoh T, Kitano M et al (2014) High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up. J Radiat Res 55(3):509\u2013517","journal-title":"J Radiat Res"},{"issue":"1","key":"2359_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.21873\/anticanres.13137","volume":"39","author":"T Makino","year":"2019","unstructured":"Makino T, Nakashima K, Iijima M et al (2019) Health-related quality of life and toxicity after single-fraction high-dose-rate brachytherapy with external beam radiotherapy for localized and locally advanced prostate cancer. Anticancer Res 39(1):477\u2013486","journal-title":"Anticancer Res"},{"issue":"9","key":"2359_CR7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/iju.14305","volume":"27","author":"T Kasahara","year":"2020","unstructured":"Kasahara T, Ishizaki F, Kazama A et al (2020) High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer. Int J Urol 27(9):800\u2013806","journal-title":"Int J Urol"},{"issue":"12","key":"2359_CR8","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.3390\/cancers14122976","volume":"14","author":"H Yamazaki","year":"2022","unstructured":"Yamazaki H, Suzuki G, Masui K et al (2022) Role of brachytherapy boost in clinically localized intermediate and high-risk prostate cancer: lack of benefit in patients with very high-risk factors T3b\u20134 and\/or Gleason 9\u201310. Cancers (Basel) 14(12):2976","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2359_CR9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s00066-021-01784-3","volume":"197","author":"K Mori","year":"2021","unstructured":"Mori K, Sasaki H, Tsutsumi Y et al (2021) Trimodal therapy with high-dose-rate brachytherapy and hypofractionated external beam radiation combined with long-term androgen deprivation for unfavorable-risk prostate cancer. Strahlenther Onkol 197(11):976\u2013985","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"2359_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach M 3rd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 65(4):965\u2013974","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"2359_CR11","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol 34(12):1402\u20131418","journal-title":"J Clin Oncol"},{"issue":"8","key":"2359_CR12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3390\/cancers13081856","volume":"13","author":"H Yamazaki","year":"2021","unstructured":"Yamazaki H, Suzuki G, Masui K et al (2021) Radiotherapy for clinically localized T3b or T4 very-high-risk prostate cancer-role of dose escalation using high-dose-rate brachytherapy boost or high dose intensity modulated radiotherapy. Cancers (Basel) 13(8):1856","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2359_CR13","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1007\/s10147-021-02023-6","volume":"26","author":"T Makino","year":"2021","unstructured":"Makino T, Sakurai T, Takamatsu S et al (2021) The effectiveness of high-dose-rate brachytherapy with external beam radiotherapy for clinically locally advanced and node-positive prostate cancer: long-term results of a retrospective study. Int J Clin Oncol 26(12):2310\u20132317","journal-title":"Int J Clin Oncol"},{"issue":"15","key":"2359_CR14","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/pros.23430","volume":"77","author":"H Tsumura","year":"2017","unstructured":"Tsumura H, Ishiyama H, Tabata KI et al (2017) Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy. Prostate 77(15):1520\u20131527","journal-title":"Prostate"},{"issue":"6","key":"2359_CR15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.brachy.2017.07.008","volume":"16","author":"JV Hegde","year":"2017","unstructured":"Hegde JV, Demanes DJ, Veruttipong D et al (2017) Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy 16(6):1106\u20131112","journal-title":"Brachytherapy"},{"issue":"3","key":"2359_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ijrobp.2019.09.044","volume":"106","author":"H Tharmalingam","year":"2020","unstructured":"Tharmalingam H, Tsang Y, Choudhury A et al (2020) External beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume. Int J Radiat Oncol Biol Phys 106(3):525\u2013533","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2359_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/cncr.31833","volume":"125","author":"D Sundi","year":"2019","unstructured":"Sundi D, Tosoian JJ, Nyame YA et al (2019) Outcomes of very high-risk prostate cancer after radical prostatectomy: validation study from 3 centers. Cancer 125(3):391\u2013397","journal-title":"Cancer"},{"issue":"5","key":"2359_CR18","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.ijrobp.2010.01.006","volume":"79","author":"DA Kuban","year":"2011","unstructured":"Kuban DA, Levy LB, Cheung MR et al (2011) Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79(5):1310\u20131317","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2359_CR19","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1016\/j.ijrobp.2011.01.063","volume":"81","author":"A Sabolch","year":"2011","unstructured":"Sabolch A, Feng FY, Daignault-Newton S et al (2011) Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 81(4):e351\u2013e360","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2359_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41391-019-0156-z","volume":"23","author":"S Kimura","year":"2020","unstructured":"Kimura S, Abufaraj M, Janisch F et al (2020) Performance of [68Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 23(1):1\u201310","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2359_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.brachy.2022.12.004","volume":"22","author":"SA Patel","year":"2023","unstructured":"Patel SA, Baumann B, Michalski J et al (2023) Association of brachytherapy boost with overall survival for Gleason 9\u201310 prostate cancer: the impact of primary versus secondary pattern 5. Brachytherapy 22:310\u2013316","journal-title":"Brachytherapy"},{"issue":"14","key":"2359_CR22","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1200\/JCO.18.02158","volume":"37","author":"SA Rosenthal","year":"2019","unstructured":"Rosenthal SA, Hu C, Sartor O et al (2019) Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG oncology RTOG 0521 trial. J Clin Oncol 37(14):1159\u20131168","journal-title":"J Clin Oncol"},{"issue":"5","key":"2359_CR23","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.brachy.2020.10.007","volume":"20","author":"K Martell","year":"2021","unstructured":"Martell K, Kollmeier MA (2021) Complications and side effects of high-dose-rate prostate brachytherapy. Brachytherapy 20(5):966\u2013975","journal-title":"Brachytherapy"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02359-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02359-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02359-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T07:10:43Z","timestamp":1690787443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02359-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2359"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02359-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"7 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}